ARV7 test

Discussion in 'Medivation' started by Anonymous, Oct 11, 2014 at 1:56 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    When will the ARV7 biomarker test be available commercially? What company will be producing it? Little response to Xtandi or Zytiga if patient tests positive for ARV7. I'm sure the payers will pay for a test to show which metastatic prostate patients get no response to these expensive orals...
     

  2. Anonymous

    Anonymous Guest

    Have a friend at Genoptix that says is company is possibly looking at commercializing ARV7 test with John Hopkins. That would be a good place to leave to especially with abbie going generic and goals will be impossible to make then.
     
  3. Anonymous

    Anonymous Guest

    Well, if this biomarker becomes commercialized by John Hopkins and some diagnostic company, we are screwed because the payors will want patients tested and 30-40% will test positive and sales will go down the tubes. Time to start looking…..
     
  4. Anonymous

    Anonymous Guest

    There artel on
    Annie's that are finalizing this. But as Abi goes generic in couple of years, issue becomes more important for use of Xtandi than Abi since physicians will use the generic drug for all since it would be cheap.
     
  5. Anonymous

    Anonymous Guest

    Had 2 med oncs in one week ask when ARV7 test will be available…yikes! Time to start looking…the word is out on that biomarker.
     
  6. Anonymous

    Anonymous Guest

    I also had 2 docs bring up the ARV7 test that was published in New Journal of Medicine 9/11/2014…time to jump to whatever company does wind up developing the test.
     
  7. Anonymous

    Anonymous Guest

    If Medivation was smart, it would commercialize the ARV7 test before JNJ partners with John Hopkins. Especially since we have a pitiful pipeline...
     
  8. Anonymous

    Anonymous Guest

    Medivation is smart. Leadership thinks about their pockets, nothing else. ARV7 test will not generate money for company especially when Abi goes generic in couple of years. Just doesn't make financial sense.